Insomnia-Focused Orexin Receptor Market to Surpass $1,436.1 Million by 2035 on Expanding Global Approvals

Orexin receptor market was valued at $800.2 million in 2025 and is projected to reach $1,436.1 million by 2035, growing at a CAGR of 6.1% during the forecast period (2026-2035).  The orexin receptor antagonists is undergoing steady expansion, driven by increasing recognition of insomnia as a chronic neurological disorder requiring targeted therapeutic intervention. Dual orexin receptor antagonists have emerged as a differentiated class, acting on wakefulness pathways rather than broadly depressing central nervous system activity. This mechanism has positioned the category as a clinically relevant alternative to traditional sedative hypnotics. Growing physician awareness, favorable safety observations, and expanding regulatory approvals are supporting commercial penetration across key markets. As a result, leading pharmaceutical companies are prioritizing lifecycle management and geographic expansion strategies within the insomnia segment.

Browse the full report description of “Orexin Receptor Market Size, Share & Trends Analysis Report by Type (Orexin 1 Receptor and Orexin 2 Receptor) and by Application (Insomnia, Anxiety, Sleep Disorders, Major Depressive Disorder and Other), (2026-2035)” a https://www.omrglobal.com/industry-reports/orexin-receptor-market

In China, the commercial introduction of DAYVIGO and QUVIVIQ in 2025 marked a notable development in the prescription insomnia therapy landscape. Both agents, classified as dual orexin receptor antagonists, were approved in mid-year and subsequently launched through major pharmaceutical e commerce platforms. Reported sales performance indicated strong early uptake, with DAYVIGO achieving substantial first month volumes on JD Health, while QUVIVIQ recorded steady initial sales following its listing on Alibaba Health. The ability to obtain these therapies through online prescription channels has supported patient accessibility. Unlike conventional sedative hypnotics, these products are not categorized as controlled psychotropic substances in China, which may contribute to broader distribution. Early commercial performance suggests potential for structural shifts within the domestic insomnia treatment market.

Key Players and Recent Regulatory & Commercial Developments

The major companies present in the global orexin receptor market include Eisai Co., Ltd., Merck & Co., Inc., Idorsia Pharmaceuticals Ltd, and Sun Pharmaceutical Industries Ltd. These market participants are advancing biologic and small-molecule interleukin-targeted therapies through late-stage clinical development, regulatory submissions, and strategic licensing partnerships to strengthen their immunology portfolios. These companies are expanding global commercialization capabilities while investing in next-generation cytokine modulation platforms to address inflammatory, autoimmune, and oncology indications.

• In February 2026, Takeda Pharmaceutical Co. Ltd. announced that the U.S. Food and Drug Administration accepted and granted Priority Review to its New Drug Application for oveporexton (TAK-861) for the treatment of narcolepsy type 1. The investigational oral orexin receptor 2 agonist is designed to restore orexin signaling and address the underlying orexin deficiency causing the disorder, with a PDUFA action date set for the third quarter of 2026.

• In December 2024, Shionogi & Co., Ltd. and Nxera Pharma Co., Ltd. announced the launch of QUVIVIQ (daridorexant) 25 mg and 50 mg in Japan for the treatment of adults with insomnia. QUVIVIQ is an oral dual orexin receptor antagonist designed to reduce excessive wakefulness by selectively targeting OX1R and OX2R receptors. Under their commercial partnership, Shionogi will lead distribution and sales activities in Japan, strengthening its focus on the quality-of-life disease segment while expanding Nxera’s commercialization footprint in the Japanese market.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Type
  • Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Eisai Co., Ltd., Merck & Co., Inc., Idorsia Pharmaceuticals Ltd, and Sun Pharmaceutical Industries Ltd., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Orexin Receptor Market Report Segment

By Type

• Orexin 1 Receptor
• Orexin 2 Receptor

By Application

• Insomnia
• Anxiety
• Sleep Disorders
• Major Depressive Disorder
• Other

Global Orexin Receptor Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/orexin-receptor-market